Table 2. Within-group comparisons of cardiometabolic risk factors for the intervention group at pre-intervention, post-intervention, and sustainability.
P-values | |||||||
---|---|---|---|---|---|---|---|
Variable | Pre-int. (0 weeks) (n = 26) | Post-int. (12 week) (n = 19) | Sustainability (24 week) (n = 19) | Pre-int. vs Post-int. | Pre-int. vs Sustainability | Post-int. vs Sustainability | Population norms/range for adult women |
Body mass (kg) | 89.8 ± 21.1 | 86.9 ± 20.5 | 86.1 ± 20.3 | 0.791 | 0.408 | 0.369 | - |
Body mass index (kg·m-2) | 32.2 ± 5.9 | 31.3 ± 0.9 | 31.0 ± 6.1 | 0.447 | 0.197 | 0.291 | 18.5–24.9 [1] |
Waist circumference (cm) | 93.1 ± 11.7 | 87.3 ± 9.8 | 87.8 ± 9.4 | < 0.001* | 0.002* | 0.696 | ≤ 80 [11] |
Hip circumference (cm) | 116.3 ± 13.3 | 114.2 ± 13.50 | 114.5 ± 13.9 | 0.309 | 0.627 | 0.734 | - |
Waist-hip-ratio | 0.79 ± 0.05 | 0.77 ± 0.04 | 0.77 ± 0.04 | 0.002* | 0.018* | 0.998 | < 0.80 [1] |
Waist-height-ratio | 0.56 ± 0.06 | 0.53 ± 0.05 | 0.53 ± 0.05 | < 0.001* | 0.001* | 0.841 | < 0.50 [35] |
Systolic BP (mmHg) | 120 ± 11 | 116 ± 9 | 116 ± 11 | 0.047* | 0.131 | 0.967 | ≤ 130 [11] |
Diastolic BP (mmHg) | 68 ± 6 | 64 ± 9 | 64 ± 6 | 0.040* | 0.050* | 0.841 | ≤ 85 [11] |
HDL-cholesterol (mM; mg·dL-1) | 1.7 ± 0.5 | 1.9 ± 0.5 | 1.9 ± 0.4 | 0.193 | 0.386 | 0.726 | ≥ 1.29 [11] |
65.6 ± 19.3 | 73.5 ± 19.3 | 73.5 ± 15.4 | ≥ 49.8 | ||||
Triglycerides (mM; mg·dL-1)# | 1.3 ± 0.5 | 1.4 ± 0.7 | 1.5 ± 1.0 | 0.855 | 0.271 | 0.221 | ≤ 1.7 [11] |
115.0 ± 44.2 | 123.9 ± 61.9 | 132.7 ± 88.5 | ≤ 150.4 | ||||
Fasting glucose (mM; mg·dL-1)# | 4.6 ± 0.4 | 4.6 ± 0.4 | 4.6 ± 0.5 | 0.728 | 0.559 | 0.756 | ≤ 5.6 [11] |
82.9 ± 7.2 | 82.9 ± 7.2 | 82.9 ± 9.0 | ≤ 100.9 | ||||
Total cholesterol (mM;mg·dL-1) | 4.4 ± 0.6 | 4.3 ± 0.8 | 4.3 ± 0.6 | 0.542 | 0.671 | 0.937 | < 5.5 [36] |
169.9 ± 23.1 | 166.0 ± 30.9 | 166.0 ± 23.1 | < 212.3 | ||||
Fasting insulin (mU·l-1)# | 9.4 ± 4.7 | 8.1 ± 2.6 | 8.8 ± 4.7 | 0.957 | 0.466 | 0.344 | - |
HOMA-IR | 1.9 ± 1.0 | 1.6 ± 0.5 | 1.80 ± 0.97 | 0.176 | 0.575 | 0.480 | < 2.0 [37] |
hsCRP (mg·l-1)# | 3.5 ± 3.0 | 4.6 ± 4.9 | 4.7 ± 3.8 | 0.743 | 0.148 | 0.140 | < 3.0 [23] |
Resting heart rate (bpm) | 76 ± 12 | 68 ± 8 | 66 ± 9 | 0.020* | 0.004* | 0.489 | - |
Predicted max (l·min-1) | 2.4 ± 0.5 | 2.8 ± 0.6 | 2.5 ± 0.6 | 0.029* | 0.471 | 0.179 | - |
Predicted max (ml·kg-1·min-1) | 27.9 ± 7.0 | 32.6 ± 6.8 | 30.9 ± 9.7 | 0.000* | 0.248 | < 0.001* | ≥ 31.0 [38] |
Physical activity (min·week-1)# | 97 ± 62 | 280 ± 67 | 143.7 ± 48.4 | < 0.001* | 0.002* | < 0.001* | ≥ 210 [39] |
Energy (kj; kcal) | 6535 ± 2183 | 5223 ± 1725 | 5538 ± 2588 | 0.007* | 0.269 | 0.161 | - |
1562 ± 522 | 1248 ± 412 | 1324 ± 618 | |||||
CHO (g) | 166 ± 74 | 178 ± 96 | 154 ± 83 | 0.638 | 0.928 | 0.638 | - |
Protein (g)# | 173 ± 86 | 138 ± 63 | 150 ± 86 | 0.012* | 0.520 | 0.079 | - |
Total fat (g)# | 66 ± 34 | 55 ± 14 | 56 ± 20 | 0.227 | 0.575 | 0.513 | - |
Data presented as mean ± standard deviation
# log10 transformation
* P ≤ 0.05.
Int, intervention. BP blood pressure, HDL high-density lipoprotein, HOMA-IR homeostasis model assessment of insulin resistance, hs-CRP high sensitivity C-reactive protein, CHO carbohydrates.